Biohaven establishes $150M at-the-market equity offering program with J.P. Morgan

Biohaven Ltd.

Agreement with J.P. Morgan Securities allows sale of up to $150M common shares via ATM program.
Sales may occur on NYSE at prevailing market prices or in negotiated transactions.
Company may sell shares periodically based on market conditions, capital needs, and other factors.
Registration statement on Form S-3 filed October 2, 2023 (File No. 333-274822).
Program provides added flexibility for potential future financing without immediate dilution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.